Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons.
van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, Steenvoorden E, Rynearson KD, Brouwers JF, Helms JB, Ovaa H, Giera M, Wagner SL, Bang AG, Goldstein LSB. · 2019
Read Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons. by van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, Steenvoorden E, Rynearson KD, Brouwers JF, Helms JB, Ovaa H, Giera M, Wagner SL, Bang AG, Goldstein LSB. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6414424.txt.
Introduction
van der Kant and co-authors report a cell study in Cell Stem Cell on cholesterol and Alzheimer's disease. Genes and population data link cholesterol handling to the disease. The team grew neurons from Alzheimer's patients' stem cells and screened them for tau buildup.
Compounds that lowered cholesteryl esters, the storage form of cholesterol, also lowered tau. The same axis controlled amyloid-beta through a separate route. Gene-edited cell lines confirmed the split control. The authors name cholesterol metabolism as a drug target in its own right. Hitting it early may slow both hallmarks of the disease.
Catalog record
| CREATOR | van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, Steenvoorden E, Rynearson KD, Brouwers JF, Helms JB, Ovaa H, Giera M, Wagner SL, Bang AG, Goldstein LSB. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 99 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons By Rik van der Kant, Vanessa F. Langness, Cheryl M. Herrera, Daniel A. Williams, Lauren K. Fong, Yves Leestemaker, Evelyne Steenvoorden, Kevin D. Rynearson, Jos F. Brouwers, J. Bernd Helms, Huib Ovaa, Martin Giera Published in: Cell Stem Cell DOI: 10.1016/j.stem.2018.12.013 ABSTRACT Summary Genetic, epidemiologic, and biochemical evidence suggests that predisposition to Alzheimer’s disease (AD) may arise from altered cholesterol metabolism, although the molecular pathways that may link cholesterol to AD phenotypes are only partially understood. Here, we perform a phenotypic screen for pTau accumulation in AD-patient iPSC-derived neurons and identify cholesteryl esters (CE), the storage product of excess cholesterol, as upstream regulators of Tau early during AD development. Using isogenic induced pluripotent stem cell (iPSC) lines carrying mutations in the cholesterol-binding domain of APP or APP null alleles, we found that while CE also regulate Aβ secretion, the effects of CE on Tau and Aβ are mediated by independent pathways. Efficacy and toxicity screening in iPSC-derived astrocytes and neurons showed that allosteric activation of CYP46A1 lowers CE specifically in neurons and is well tolerated by astrocytes. These data reveal that CE independently regulate Tau and Aβ and identify a druggable CYP46A1-CE-Tau axis in AD. INTRODUCTION Pathological accumulation of phosphorylated Tau (pTau) and accumulation of amyloid-beta (Aβ) fragments are the two major biochemical hallmarks of Alzheimer’s disease (AD). Effective strategies to remove Aβ in AD-patient brains have been developed but have not yet shown efficacy to slow cognitive decline in clinical trials. This finding has led to the idea that targeting Tau or combinatorial strategies that target both Tau and Aβ are required to treat AD. While Aβ generation has been studied in much detail, the processes that drive pTau accumulation in AD are poorly defined. Late stage Tau pathology, such as aggregation of accumulated Tau in neurofibrillary tangles (NFT), and subsequent neurodegeneration can be modeled in mice, or non-neuronal human cells, by (over)expression of human mutant Tau. However, Tau mutations do not occur in AD. Instead, in AD, endogenous “wild-type” pTau accumulates downstream of familial AD (FAD) mutations (in APP, PSEN1, and PSEN2 genes) or, in the case of sporadic late-onset AD (SAD), downstream of an unknown combination of genetic and environmental risk factors. How these factors drive early accumulation of pTau in AD is not understood. Recent advances in induced pluripotent stem cell (iPSC) technology (Shi et al., 2017) have made it possible to generate functional human neurons from patients and healthy controls to study early pathophysiological regulation of endogenous Tau. In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012). Accumulation of pTau in FAD neurons can be reversed by inhibition of β-secretase, the enzyme that converts APP to β-CTF indicating a direct relationship between APP processing and Tau (Israel et al., 2012, Moore et al., 2015). Interestingly, inhibition of γ-secretase (to prevent generation of Aβ from β-CTF) did not reduce pTau, indicating that the effect of APP processing on pTau in early AD neurons is not solely mediated by extracellular Aβ (Israel et al., 2012, Moore et al., 2015). Identification of other cellular pathways that contribute to pTau accumulation early in FAD and SAD neurons is key to understanding Tau pathology in AD. In addition to increased Aβ and pTau levels, CE also accumulate in FAD and SAD. CE are increased in mouse models expressing human (mutant) APP (Chan et al., 2012, Tajima et al., 2013, Yang et al., 2014) and CE, as well as CE-storage organelles (lipid droplets), have been shown to accumulate in the SAD brain (Chan et al., 2012, Foley, 2010, Hamilton et al., 2015, Yang et al., 2014). CE are generated when cholesterol is converted to CE by the ER-resident Acyl-CoA cholesterol acyltransferase (ACAT) through ligation of a long-chain fatty acid to (excess) cholesterol, and CE can be converted back to cholesterol by acidic lipases in the lysosome (Ikonen, 2008, Puglielli et al., 2003). CE enhance the production of Aβ in vivo and in vitro indicating that CE can contribute to AD pathogenesis (Di Paolo and Kim, 2011, Hutter-Paier et al., 2004, Huttunen et al., 2009, Puglielli et al., 2001, Puglielli et al., 2003). CE-dependent regulation of Aβ generation is mediated by altered trafficking of APP through the early secretory pathway (Huttunen et al., 2009). Whether CE also affect Tau phosphorylation or Tau proteostasis is unknown, but inhibition of cholesterol esterification by genetic deletion of ACAT1 prevents early stage Tau pathology in Tau mutant mice through unknown mechanisms (Shibuya et al., 2015). A possible way by which CE could affect Tau pathology is through regulation of the ubiquitin-proteasome system (UPS). Cholesterol and cholesterol metabolites extensively interact with the UPS to regulate the ubiquitination and degradation of cholesterol-metabolic enzymes (Sharpe et al., 2014), and the UPS is a major regulator of pTau proteostasis. (Lee et al., 2013). Activity of the UPS is decreased in AD (Keck et al., 2003, Keller et al., 2000), and UPS (re)activation delays Tau aggregation and neurodegeneration in vitro and in vivo (Han et al., 2014, Lokireddy et al., 2015, Myeku et al., 2016). Here, we tested a library of >1,600 compounds for their potency to inhibit pTau accumulation in cultured FAD iPSC-derived neurons and find that neuronal CE regulate the proteasome-dependent degradation of pTau. Using neurons derived from multiple AD- and non-demented control (NDC) iPSC lines, as well as isogenic CRISPR/Cas9 gene-edited lines, we demonstrate that the effect of CE on pTau is correlated with, but independent of APP processing and Aβ. Whereas the effect of CE on pTau is mediated by proteasomal upregulation, the effect of CE on Aβ secretion is mediated by a cholesterol-binding domain in APP. We identify a number of strategies to reduce pTau in a CE-dependent manner and find that allosteric activation of CYP46A1 is a neuron-specific CE-lowering strategy particularly well tolerated by human astrocytes. Collectively, our data identify a CYP46A1-CE-Tau axis as an early druggable pathway in AD. RESULTS A Drug Screen in iPSC-Derived Human FAD Neurons to Identify Compounds that Reduce pTau Accumulation pThr231Tau is an early marker of AD pathology that correlates well with cognitive decline (Buerger et al., 2002, Luna-Muñoz et al., 2007). pThr231Tau accumulates in APP duplication (APPdp) iPSC-derived FAD neurons (Israel et al., 2012). To identify compounds that reduce pTau accumulation in these FAD neurons, we screened a collection of 1,684 approved and preclinical drugs for their efficacy to lower neuronal pThr231Tau. For our screen, neural progenitor cells (NPCs; line APPdp1-6) (Israel et al., 2012) were differentiated to neurons (Figures S1A and S1B) for 3 weeks, replated in 384 well plates, and allowed to mature for 2 weeks before treatment with compound at 5 μM for 5 days. The screen was performed in duplicate, and a ratiometric readout of pThr231Tau/total Tau (tTau) level and cell viability was determined (Figure 1A). In the primary screen, 158/1,684 compounds (9.4%) significantly reduced pThr231/tTau by a Z score <−2 in at least one of the duplicates (Figure 1B; Tables S1 and S2) and were selected